2.20Open2.20Pre Close0 Volume3 Open Interest5.00Strike Price0.00Turnover975.13%IV-14.89%PremiumJan 17, 2025Expiry Date3.46Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8692Delta0.0377Gamma2.13Leverage Ratio-0.3689Theta0.0002Rho1.85Eff Leverage0.0012Vega
GH Research Stock Discussion
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
6 minutes ago, 4:00 AM PST
Via GlobeNewswire
GHRS
Share
• Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points (p<0.0001, n=10) and 100% of patients in remission at Day 8
• Primary endpoint met in phase 2a POC t...
• $ACADIA Pharmaceuticals (ACAD.US)$ : Jefferies Upgrades to Buy from Hold - PT $25 (from $22)
• $Arthur J. Gallagher (AJG.US)$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $185 (from $182)
• $Apple Hospitality REIT Inc (APLE.US)$ : B.Riley Upgrades to Buy from Neutral - PT $19
• $AutoZone (AZO.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $2,420 (from $2,125)
• $Boeing (BA.US)$ : Citigroup Upgr...
No comment yet